<DOC>
	<DOCNO>NCT02191384</DOCNO>
	<brief_summary>The purpose study determine whether Orcinoside Capsule different dos effective treatment Depression . And explore preliminary information safety efficacy Orcinoside Capsule Chinese Patients Depression .</brief_summary>
	<brief_title>Comparison Orcinoside With Placebo Treatment MDD</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Adult primary diagnosis major depressive disorder base criterion DSMIVTR , single episode recurrent episode , accompany psychotic symptom . Coding diagnosis include : 296.21 MDD single episode , mild 296.22 MDD single episode , moderate 296.31 MDD recurrent episode , mild 296.32 MDD recurrent episode , moderate The subject outpatient . The subject man woman , aged≥18 ≤65 year . The total score HAMD17 ≥18 ≤24 screen visit baseline visit . The subject willing take birth control measure study period one month study . The subject understands consent take part clinical trial . The subject sign inform consent . The subject significant risk suicide accord investigator 's opinion score ≥3 item 3 ( suicide assessment ) HAMD make suicide attempt . The subject current DSMⅣTR axisⅠpsychiatric diagnosis depression . When HAMD17 score baseline visit compare screen visit , decrease rate ≥25 % . The subject current diagnosis history depression due psychotic disorder general medical condition , bipolar disorder , depression accompany psychotic symptom . Any unstable cardiovascular , hepatic , renal , endocrine ( thyroid gland dysfunction ) , blood , medical disease . Had history seizure disorder brain organic disorder . The subject diagnosis alcohol substance abuse dependence least 1 year prior baseline visit . Known hypersensitivity Common Curculigo Rhizome drug . Women pregnant , breastfeeding , plan become pregnant study . Men request fertility within half year . Clinically significant electrocardiographic ( ECG ) abnormalities abnormal laboratory value ( eg . Hepatic function 1.5 time clinical toplimit , renal function toplimit , blood glucose toplimit , cardiac troponin abnormal , thyroid gland examine index significantly abnormal ) . The subject use antidepressant drug normally 2 week screen , stop use psychotropic drug le 7 halflife period ( monoamine oxidase inhibitor 2 week , fluoxetine 1 month ) . The subject accept electroconvulsive therapy within 3months . The subject accept system psychotherapy within 3 month . The compliance subject poor . The subject participate drug clinical trial within 30 day screen . The investigator think subject unsuitable enrol clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>